The Role of Amantadine Withdrawal in 3 Cases of Treatment-Refractory Altered Mental Status.

Authors:
Christopher G Pelic
Christopher G Pelic
Ralph H. Johnson VA Medical Center
James Fox
James Fox
Massachusetts Institute of Technology
United States
Gregory Sahlem
Gregory Sahlem
Medical University of South Carolina
United States
Sophie Robert
Sophie Robert
South Carolina College of Pharmacy
United States
Gonzalo J Revuelta
Gonzalo J Revuelta
Medical University of South Carolina

J Psychiatr Pract 2017 May;23(3):191-199

FRYML, WILLIAMS, PELIC, FOX, SAHLEM, ROBERT, and SHORT: Department of Psychiatry & Behavioral Sciences, Medical University of South Carolina, Charleston, SC REVUELTA: Department of Neurology and Neurosciences, Medical University of South Carolina, Charleston, SC.

Amantadine, which was originally developed as an antiviral medication, functions as a dopamine agonist in the central nervous system and consequently is utilized in the treatment of Parkinson disease, drug-induced extrapyramidal reactions, and neuroleptic malignant syndrome. For reasons that are not entirely understood, abrupt changes in amantadine dosage can produce a severe withdrawal syndrome. Existing medical literature describes case reports of amantadine withdrawal leading to delirium, which at times has progressed to neuroleptic malignant syndrome. Amantadine withdrawal may be under-recognized by mental health clinicians, which has the potential to lead to protracted hospital courses and suboptimal outcomes. The goal of this case series is to highlight the role of amantadine withdrawal in the cases of 3 medically complex patients with altered mental status. In the first case, the cognitive side effects of electroconvulsive therapy masked acute amantadine withdrawal in a 64-year-old man with Parkinson disease. In the second case, a 75-year-old depressed patient developed a catatonic delirium when amantadine was discontinued. Finally, a refractory case of neuroleptic malignant syndrome in a 57-year-old patient with schizoaffective disorder rapidly resolved with the reintroduction of outpatient amantadine. These cases highlight several learning objectives regarding amantadine withdrawal syndrome: First, it may be concealed by co-occurring causes of delirium in medically complex patients. Second, its symptoms are likely to be related to a cortical and limbic dopamine shortage, which may be reversed with electroconvulsive therapy or reintroduction of amantadine. Third, its clinical presentation may occur on a spectrum and may include features suggestive of delirium, catatonia, or neuroleptic malignant syndrome.

Download full-text PDF

Source
http://dx.doi.org/10.1097/PRA.0000000000000237DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
May 2017
52 Reads

Publication Analysis

Top Keywords

amantadine withdrawal
24
neuroleptic malignant
16
malignant syndrome
16
amantadine
10
role amantadine
8
altered mental
8
complex patients
8
parkinson disease
8
withdrawal syndrome
8
withdrawal cases
8
medically complex
8
electroconvulsive therapy
8
mental status
8
withdrawal
7
syndrome
6
case
5
cases medically
4
courses suboptimal
4
syndrome concealed
4
hospital courses
4

Similar Publications